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Abstract: The possibility that an increased intracellular con- 
centration of cyclic AMP (CAMP) can regulate the extent of 
muscarinic receptor-stimulated phosphoinositide (PPI) turn- 
over in the human neuroblastoma cell line SK-N-SH was 
examined. Addition of either forskolin (or its water-soluble 
analog, L-85,805 I), theophylline, isobutylmethylxanthine, or 
cholera toxin, agents that interact with either the catalytic 
unit of adenylate cyclase, cAMP phosphodiesterase, or the 
guanine nucleotide binding protein linked to adenylate cy- 
clase activation, resulted in a 45-1 8 1% increase in cAMP 
concentration and a 27-7076 inhibition of carbachol-stimu- 
lated inositol phosphate release. Through the use of digitonin- 
permeabilized cells, the site of inhibition was localized to a 
step at, or distal to, the guanine nucleotide binding protein 
that regulates phospholipase C activity. In contrast, when 
intact SK-N-SH cells were exposed to prostaglandin E l ,  the 
ensuing increases in cAMP were not accompanied by an in- 
hibition of stimulated PPI turnover. These differential effects 
of increased cAMP concentrations on stimulated PPI turn- 
over may reflect the compartmentation of CAMP within SK- 
N-SH cells. Key Words: Phosphoinositide-Cyclic AMP- 
Muscarinic receptor-Human neuroblastoma, SK-N-SH- 
Forskolin-Cholera toxin. Akil M. and Fisher S. K. Mus- 
cannic receptor-stimulated phosphoinositide turnover in 
human SK-N-SH neuroblastoma cells: Differential inhibition 
by agents that elevate cyclic AMP. J. Neurochem. 53, 1479- 
1486 (1989). 
The hydrolysis of inositol lipids and regulation of 
adenylate cyclase activity constitute two of the major 
signal transduction pathways in both neural and non- 
neural cells. The possibility that cross-talk exists be- 
tween these two signaling pathways has been suggested 
and evidence for cyclic AMP (CAMP)-mediated inhi- 
bition of stimulated phosphoinositide (PPI) hydrolysis 
has been obtained in some nonneural tissues (Nishi- 
zuka, 1986; Della Bianca et al., 1986; Jakobs et al., 
1986; Neylon and Summers, 1988; Madison and 
Brown, 1988). However, little information exists to in- 
dicate whether a similar regulation of PPI turnover by 
cAMP also occurs in neural tissues. 
In the present study, we have utilized the human 
neuroblastoma cell line SK-N-SH to determine whether 
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elevated intracellular concentrations of cAMP result 
in an inhibition of receptor-stimulated PPI turnover. 
These cells appear well suited to such a study because 
they are homogeneous and possess receptors that are 
linked to the regulation of adenylate cyclase activity 
(Yu et al., 1986, 1988; Baron and Siegel, 1988). Fur- 
thermore, SK-N-SH neuroblastomata possess a high 
density of muscarinic cholinergic receptors (mAChRs) 
that are effectively coupled to  PPI turnover, both in 
intact and permeabilized cells (Fisher and Snider, 1987; 
Fisher, 1988; Fisher et al., 1989). Our studies indicate 
that the addition of selective agents that elicit an in- 
creased intracellular concentration of cAMP indepen- 
dent of receptor activation also results in an inhibition 
of mAChR-stimulated PPI turnover in SK-N-SH cells. 
GTPrS, guanosine-S-O-(3-thiotriphosphate); IBMX, 3-isobutyl-l- 
methylxanthine; IP, inositol phosphate(s) (inositol mono-, bis-, 
tris-, and tetrakisphosphates); IPI , inositol monophosphate; L- 
85,805 1, 7@-deacetyl-7P-(y-N-methylpiperazino)butyryl forskolin; 
mAChR, muscarinic acetylcholine receptor; NMS, N-methylscopo- 
lamine; PGEl , prostaglandin E, ; PPI, phosphoinositide (phosphati- 
dylinositol, phosphatidylinositol4-phosphate, and phosphatidylino- 
sitol 4,5-bisphosphate); SDS-PAGE, sodium dodecyl sulfate-poly- 
acrylamide gel electrophoresis. 
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Using digitonin-permeabilized cells, we demonstrate 
that the inhibition can be localized to a site that is 
either at, or distal to, the guanine nucleotide binding 
protein (GJ that regulates phospholipase C activity. 
In marked contrast, prostaglandin El  (PGEl)-mediated 
increases in cAMP do not elicit an inhibition of stim- 
ulated PPI turnover, a result consistent with the pos- 
sibility that the effects of CAMP on inositol lipid turn- 
over are compartmentalized in SK-N-SH cells. A pre- 
liminary report of part of this work has appeared 
elsewhere (Akil and  Fisher, 1988). 
MATERIALS AND METHODS 
rnyo-[2-3H]lnositol ( 1  5 Ci/mmol) was obtained from 
American Radiolabeled Chemicals (St. Louis, MO. U.S.A.). 
N-[3H]Methylscopolamine (['HINMS) (80 Ci/mmol) was 
obtained from New England Nuclear (Boston, MA, U.S.A.). 
Forskolin (FSK), 3-isobutyl-I-methylxanthine (IBMX). 2-0- 
dibutyryl cyclic AMP (dBcAMP), theophylline. carbachol, 
and 8-bromo-cyclic GMP (8BcGMP) were obtained from 
Sigma Chemical (St. Louis, MO. U.S.A.). Guanosine 5'-0- 
(3-thiotriphosphate) (GTPyS) was purchased from Boeh- 
ringer-Mannheim (Indianapolis, IN, U.S.A.). Cholera toxin 
(CT), 1,9-dideoxyforskolin, 7-0-hemisuccinyl-7-deacetyl 
forskolin, and 7@-deacetyl-7@-(y-lmethylpiperazino)butyryl 
forskolin (L-85.805 I ) were obtained from Behring Diagnos- 
tics (La Jolla, CA, U.S.A.). Dowex-l (100-200 mesh: X8 in 
the formate form) was obtained from Bio-Rad Laboratories 
(Rockville Center, NY, U.S.A.). Tissue culture supplies were 
obtained from Corning Glass Works (Corning. NY, U.S.A.). 
Powdered Dulbecco's modified medium and fetal bovine 
serum were purchased from Grand Island Biological (Grand 
Island, NY, U.S.A.). ["PINAD (39 Ci/mmol) was obtained 
from New England Nuclear (Boston. MA, U.S.A.). 
Cell culture conditions 
Human SK-N-SH neuroblastoma cells were cultured in 
Dulbecco's modified Eagle's medium/ 10% fetal calf serum 
in an atmosphere of 90% air/lO% C 0 2  under conditions that 
have been described previously by Fisher and Snider ( 1987). 
Cells were first detached from tissue culture dishes by aspi- 
ration of the medium and the addition of 10 ml of Puck's 
DI solution (Honegger and Richelson, 1976). They were then 
collected by centrifugation at 300 g for 1 rnin and resuspended 
in buffer A (142 mM NaCI, 5.5 mhf KCI, 2.2 mM CaCI2. 
3.6 mM NaHCO,, 1 mM MgC12, 5.6 mM D-glucose. and 30 
mM Na+ HEPES buffer, pH 7.4). Cells utilized were 10-20 
days old. Protein determinations were performed by the 
method of Geiger and Bessman (1972). 
Determination of PPI turnover 
Intact SK-N-SH cells were harvested as described above. 
then resuspended in buffer A containing [3H]inositol (ap- 
proximately 9 pCi/ml) at a protein concentration of 0.8-2 
mg/ml protein. Cells were first allowed to prelabel for 45 rnin 
at 37°C. and then incubated (unless specified otherwise) for 
an additional 45 rnin in the presence or absence of carbachol 
(10 mM),  the various agents, and 10 mM LiCl (final volume, 
0.5 ml). Reactions were terminated by the addition of 1.5 ml 
of chloroform/methanol ( I  :2. vol/vol) and the total water- 
soluble inositol phosphate (IP) fraction was separated and 
quantitated by ion-exchange chromatography as previously 
described by Fisher and Snider (1987). Both basal and car- 
bachol-stimulated release of 3H-IP was linear with time over 
a 45-min incubation period. In other experiments, individual 
IP species were fractionated as previously described by Fisher 
and Bartus (1985) and Fisher et al. (1989). Approximately 
75% of the label was recovered in inositol monophosphate 
UPl), with the remainder present in glycerophosphorylinosi- 
tol, inositol bisphosphate. inositol trisphosphate, and inositol 
tetrakisphosphate. In some experiments, a 200-pl aliquot was 
removed from the organic phase to determine the incorpo- 
ration of [3H]inositol into the phospholipid fraction (Fisher 
and Bartus, 1985). 
Determination of intracellular cAMP levels 
SK-N-SH cells (0.8-2 mg protein/ml) were incubated with 
various agents for 45 min at 37°C (unless otherwise specified). 
Reactions were terminated by immersing the tubes in ice- 
cold water followed by centrifugation at 2,500 g for 3 min. 
The supernatant was discarded, and the pellet extracted with 
1 ml of 7% perchloric acid. The extract was then neutralized 
with K2CO3 (1.77 M ) ,  dried down under N2, and resuspended 
in 50 mM sodium acetate buffer (pH 6.2). cAMP quantitation 
was performed using a cAMP I2'I radioimmunoassay kit from 
New England Nuclear (Boston, MA, U.S.A.). In most ex- 
periments, CAMP determinations were carried out on the 
same incubations utilized for PPI turnover measurement. 
CT treatment 
Intact cells. SK-N-SH cells were cultured in Dulbecco's 
modified Eagle's medium/ 10% fetal calf serum containing 
50 pg/ml CT for 5 or 24 h. Cells were then harvested, pre- 
labeled with [3H]inositol for 60 min, and incubated for 45 
min at 37°C in the presence or absence of carbachol. The 
release of labeled IPS and/or cAMP concentrations deter- 
mined were measured as described above. 
Permeubilized cells. Cells were prelabeled for 3 days in 
medium containing 5-7.5 pCi/ml of [3H]inositol. In one set 
of experiments CT was added to tissue culture dishes at a 
concentration of 50 pg/ml for an overnight incubation (ap- 
proximately 16 h). Cells were then harvested and perme- 
abilized with digitonin as previously described by Fisher et 
al. (1989). prior to incubation with carbachol, GTPyS, or 
both for 15 min at 37°C and measurement of IP release. In 
a second series of experiments, prelabeled cells were first per- 
meabilized, and then incubated with activated CT (Tamir 
and Gill, 1988) at a concentration 50 Fg/ml for 30-60 min. 
Release of labeled IPS was then measured following a 15- 
rnin incubation with carbachol, GTPyS, or a combination 
of the two agents. 
ADP-ribosylation of SK-N-SH cells 
with ["P)NAD and CT 
Control or CT-pretreated SK-N-SH cells were homoge- 
nized in 50 mhf sodium phosphate buffer (pH 7.4) containing 
protease inhibitors (10 pg/ml of leupeptin, aprotinin, and 
soybean trypsin inhibitor). Homogenates were then centri- 
fuged at 500 g/5 min. pellets discarded, and supernatants 
centrifuged at 14,000 g/lO min. The pellets were then resus- 
pended in 100 mMpotassium phosphate buffer (pH 7.5) and 
membranes from control or CT-pretreated cells incubated in 
the absence or presence of activated CT (100 pg/ml: Tamir 
and Gill, 1988) with [32P]NAD under the conditions described 
by Klinz et al. (1987). [32P]ADP-nbosylated membrane pro- 
teins were analyzed by sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis (SDS-PAGE; Laemmli, 1970) and 
visualized autoradiographically as previously described by 
Fisher and Heacock (1 988). 
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Radioligand binding 
The binding of ['HINMS to mAChRs on intact SK-N-SH 
cells was determined as previously described by Fisher (1 988). 
Data analysis 
Values quoted are means +- SEM for the number of sep- 
arate experiments stated in parentheses. Student's two-tailed 
t tests were used to evaluate the statistical differences of the 
means of paired or unpaired sets of data. Percent inhibition 
of carbachol-stimulated 3H-IP release was calculated from 
the equation: 
Percent inhibition = [ I  - pc] X 100
where A is 'H-IP release observed in the presence ofcarbachol; 
B is 'H-IP release observed in the presence of carbachol and 
inhibitory agent; C is basal 3H-IP release observed in control 
incubations; and D is basal 'H-IP release observed in control 
incubation containing the inhibitory agent. A negative value 
indicates that carbachol-stimulated 3H-IP release was higher 
in the presence of the agent than in its absence. 
RESULTS 
Inhibition of carbachol-stimulated 3H-IP release 
by FSK 
Incubation of [3H]inositol-prelabeled SK-N-SH cells 
with 50 pA4 FSK, a diterpene that directly stimulates 
the catalytic subunit of adenylate cyclase (Seamon and 
Daly, 1986), resulted in a 41 f 4% inhibition of car- 
bachol-stimulated 3H-IP release (n = 16). Addition of 
FSK also inhibited the ability of carbachol to stimulate 
the labeling of the inositol lipid fraction (33 f 4% in- 
hibition, n = 1 l), whereas no effect of FSK on basal 
lipid labeling was observed. The inhibitory effect of 
FSK was dose dependent with little effect detectable at 
10 pA4 and maximum inhibition observed at 100 pM 
FSK, a concentration close to the solubility limit of 
FSK (Seamon and Daly, 1986) (Fig. 1). In all subse- 
- FSK - 10 
' 
2 5  50 7 5  100 
FSK concentration (JIM) 
FIG. 1. Concentration dependence of FSK inhibition of stimulated 
3H-JP release. Prelabeled SK-N-SH cells were incubated with in- 
creasing concentrations of FSK for 45 min at 37°C in the presence 
(m) or absence (0) of carbachol(10 mM). Values shown are means 
f SEM for triplicate samples from a single experiment. Where 
error bars are not shown, they fall inside the symbol. In three or 
four separate experiments, the addition of 10.25, 50, and 100 pM 
FSK resulted in 12 +- 7, 22 f 8. 37 * 7, and 66 * 6% inhibition of 
carbachol-stimulated 'H-IP release. Total inositol phosphate release 
was measured as described in Materials and Methods. 
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FIG. 2. Time course of FSK inhibition of carbachol-stimulated 'H- 
IP release. Prelabeled SK-N-SH cells were incubated for the des- 
ignated times at 37°C: Control (0); FSK (m); carbachol(0); carbachol 
plus FSK (0). Values shown are means * SEM for triplicate samples 
from a single experiment. In four separate timecourse experiments, 
values for the percentage inhibition of carbachol-stimulated 3H-IP 
release obtained with 50 &I FSK at 5, 10, 20, and 40 min of 
incubation were 24 f 16, 54 f 8, 34 f 9, and 39 ? 12, respectively. 
quent experiments, a concentration of 50 pA4FSK was 
used. The inhibitory effects of FSK on carbachol-stim- 
ulated 3H-IP release were detectable within the first 5- 
10 min of incubation, and persisted for up to at least 
40 min (Fig. 2). Although FSK reduced the extent of 
carbachol-stimulated 'H-IP release, the concentration 
of agonist required to elicit a half-maximal increase in 
PPI turnover was not altered, indicating that FSK does 
not change the agonist's affinity for the mAChR 
(Fig. 3). 
Because some of the effects of FSK have been pre- 
viously ascribed to mechanisms that do not involve 
adenylate cyclase activation (Joost et al., 1988), addi- 
tional experiments were conducted using either 7-0-  
O k j b ; ;  
-lag [Carbachol](Ml 
FIG. 3. Effect of FSK on dose dependence of carbachol-stimulated 
3H-IP release. Cells were incubated with carbachol at the indicated 
concentrations in the absence (0) or presence (0) of 50 &I FSK. 
FSK did not alter basal 3H-IP release. Values shown are means 
f SEM for triplicate samples obtained from a single experiment. 
In the experiment shown, ECM values for carbachol (calculated by 
log-probit analysis) were 80 &l (presence of FSK) and 120 &4 
(absence of FSK). In three separate experiments the mean values 
for the ECw were 130 * 21 pM (absence of FSK) and 177 f 73 
pM (presence of FSK). 
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TABLE 1. Effects of FSK and analogs on carbachol- 
srimulated 'H-IP release and inosilol lipid labeling 
Inhibition (%) 
Agent IP Inositol lipids 
FSK, 50 p M  41 -+4(16) 33+4(11) 
7-0-Hemisuccinyl-7-deacetyl FSK. 
50 pM 25i4(8) I 1  - + 4 ( 6 )  
1,9-Dideoxy FSK, 50 p M  2 t 8 ( 5 )  
L-85,805 I .  50 F M  27 2 8 (3) 20 k 8 (3) 
200 p M  56 i- 6 (3) 25 5 8 (3) 
5 2 8 ( 5 )  
Cells were first prelabeled with ['H]inositol for 45 min and then 
incubated for an additional 45 min at 37°C with carbachol(10 mM), 
in the presence or absence of the agent shown. LiCl (10 mM) was 
included in the assays during the incubation period lo prevent the 
degradation ofthe primary IP formed, 1.e.. IP, . Basal and stimulated 
'H-IP release and inositol lipid labeling were determined as described 
in Materials and Methods. Values shown are percent inhibition of 
carbachol-stimulated 'H-IP release or inositol lipid labeling (means 
+ SEM) or  range (n = 2 )  for the number of separate experiments 
indicated in parentheses. Basal 'H-IP release and inositol lipid labeling 
were not affected by any of the agents listed. 
hemisuccinyl-7-deacetyl FSK, an active structural an- 
alog of FSK (Pfeuffer and Metzger, 1982), L-85,805 1, 
an active water-soluble FSK analog (Laurenza et al., 
1987), or 1,9-dideoxy FSK, an inactive hydrophobic 
FSK analog (Laurenza et al., 1987). Addition of either 
7-0-hemisuccinyl-7-deacetyl FSK or the water-soluble 
analog L-85,805 1 significantly inhibited carbachol- 
stimulated 3H-lP production (Table I ) .  In contrast, the 
addition of 1,9-dideoxy FSK had little or no effect on 
stimulated 3H-IP release (Table 1). It appears, therefore, 
that the ability of FSK to inhibit carbachol-stimulated 
PPI hydrolysis is mediated directly through its acti- 
vation of adenylate cyclase and is not a function of its 
hydrophobicity. 
Inhibition of carbachol-stimulated 3H-IP release by 
IBMX, theophylline, and dBcAMP 
The addition of either IBMX or theophylline, both 
known inhibitors of CAMP phosphodiesterase, resulted 
in a 5 1-70% inhibition of carbachol-stimulated 3H-IP 
release, whereas basal IP release was unaffected (Table 
2, part A). Similarly, these agents also inhibited car- 
bachol-stimulated inositol lipid labeling, whereas no 
effect on basal lipid labeling was observed. When IBMX 
was included in incubations containing FSK, the re- 
sulting inhibition (85 & 8, n = 3 )  was less than additive 
( p  < 0.05), a result indicative of a common site of 
action for these two agents. In contrast to the marked 
effects of inhibitors of cAMP phosphodiesterase on 
carbachol-stimulated 3H-IP release, direct addition of 
the cell permeant analog of CAMP, dBcAMP, at a con- 
centration of 1 mM had only a modest inhibitory effect 
( 1 1 YO), the extent of which vaned considerably between 
experiments (Table 2, part B). The direct addition of 
8BcGMP was without effect. 
Effects of FSK and inhibitors of cAMP 
phosphodiesterase on ligand binding to mAChRs 
on SK-N-SH cells 
The inhibitory effects of FSK (and analogs), IBMX, 
or theophylline on mAChR-stimulated PPI turnover 
do not appear to be mediated through an inhibition of 
ligand binding to the mAChR, because none of the 
agents tested had a significant effect on the binding of 
[3H]NMS to binding sites on intact cells. Thus, in three 
separate experiments, specific [3H]NMS binding in the 
presence of 50 pA4 concentrations of FSK, 1,9-dideoxy 
FSK, 7-0-hemisuccinyl-7-deacetyl FSK, or L-85,805 1 
was 100 f 0,97 * 2,97 k 3 ,  and 102 f 4% of control, 
respectively. [3H]NMS binding obtained in the pres- 
ence of 1 mM IBMX or 2 m M  theophylline was 99 
& 6 and 94 f 4% of control, respectively. 
Intracellular cAMP concentrations 
The basal concentration of CAMP in SK-N-SH cells, 
measured under the same conditions as those employed 
for PPI turnover, was 24 f 2 pmol/mg protein (n 
= 12). To establish whether cAMP intracellular con- 
centrations were increased in the presence of FSK, 
IBMX, and theophylline, changes in the concentration 
of cAMP were measured. FSK (50 pA4) increased the 
concentration of cAMP to 281 -+ 62% of control (n 
= 6), IBMX ( I  mM) to 228 & 22% of control (n = lo), 
and theophylline (2 mM) to 171 & 40% of control (n 
= 3). cAMP could not be measured in the presence of 
dBcAMP or 8BcGMP because of cross-reactivity in 
the radioimmunoassay. Thus, the agents that inhibit 
stimulated PPI turnover also elicit a measurable in- 
crease in the concentration of CAMP in SK-N-SH cells. 
Inhibition of carbachol-stimulated 3H-IP release 
by 
mAChR-stimulated PPI turnover was also inhibited 
by preincubation of SK-N-SH cells with CT, an agent 
known to activate adenylate cyclase through ADP-ri- 
bosylation of the or-subunit of a stimulatory guanine 
nucleotide binding protein (Gs; Gilman, 1987). Prein- 
TABLE 2. Effeccts of (A) inhibitors ofcAMP 
phosphodieslerasc. (B) cell-permeant cyclic nucleotide 
analogs, and (C) CT on carbachol-stimulated 'H-IP 
release and itiosictol lipid labeling 
Agent 
~ 
(A )  
IBMX, 1 mM 
Theophylline. 2 mM 
dBcAMP. I mM 
8BcGMP. I m M  
CT. 50 pg/ml 
(B) 
( C )  
5 h  
24 h 
Inhibition (%) 
IP Inositol lipids 
5 1  - + 3  (15) 23 f 5 (12) 
70 f 2 (6) 59 i- 8 (3)  
I l k 5  ( 1 1 )  10 t 5 ( 1 1 )  
-12 t 3 (4) -2 f 2 (3) 
45 i- l O ( 3 )  42 2 1 I ( 2 )  
37 k 4 (7) 33 f 4 (3) 
~~ 
See footnote to Table 1 for experimental details. 
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FIG. 4. [32P]ADP-ribosylation of 
control or CT-pretreated cells by 
CT. Intact SK-N-SH cells were pre- 
treated in the absence or presence 
of CT (50 wg/ml) for 24 h. Mem- 
brane preparations were then ex- 
posed to [32P]NAD and activated 
CT for 30 min, as described in Ma- 
terials and Methods. Samples were 
then electrophoresed on SDS- 
PAGE. Lanes 1 and 2, control Cells; 
lanes 3 and 4, CT-pretreated cells. 
+/-CT, membranes incubated in 
presence or absence of CT. Note 
the absence of labeling of the 42- 
and 46-kilodalton bands in lane 4, 
indicating that previous ADP-ribo- 
sylation with endogenous NAD had 
occurred. 
cubation of intact cells with CT (50 pg/ml) for either 
5 h or 24 h inhibited carbachol-stimulated 3H-IP release 
by 37-45%, whereas basal 3H-IP release remained un- 
affected. Carbachol-stimulated, but not basal, phos- 
pholipid labeling was also inhibited by CT pretreatment 
(Table 2, part C). When IBMX (1 M) was added to 
CT-pretreated cells, there was a further increase in the 
inhibition of carbachol-stimulated 3H-IP release (6 1 
5 5%, n = 3). However, the sum of CT- and IBMX- 
mediated inhibitions was consistently found to be less 
than additive ( p  < 0.05). Preincubation of SK-N-SH 
cells with CT prevented the subsequent [32P]ADP-ri- 
bosylation of two membrane proteins of 42 and 46 
kilodaltons (Fig. 4), indicating that ADP-ribosylation 
with endogenous NAD had occurred. Furthermore, in 
three separate experiments either a 5-h or 24-h pre- 
treatment of SK-N-SH cells with CT reduced (by 84- 
89%) the ability of PGE, (an agonist that couples to 
adenylate cyclase activation through GJ to increase 
cAMP concentration. Whereas a 5-h CT pretreatment 
increased cAMP concentration to 145-187% of control, 
this increase was not observed following a 24-h pre- 
treatment (1 12 * 10% of control, n = 6). This may be 
attributable to an efflux of cAMP from cells that oc- 
curred during the prolonged incubation, as previously 
noted for bovine chromaffin cells (Chern et al., 1988). 
Inhibition of stimulated PPI turnover by cAMP 
in permeabilized cells 
To probe the site of action of CAMP on stimulated 
PPI turnover, digitonin-permeabilized SK-N-SH cells 
were employed. The addition of carbachol or GTPyS 
to permeabilized cells elicited a large increase in the 
release of 3H-IP, as previously observed (Fisher et al., 
1989). Overnight preincubation with CT (50 pg/ml) or 
dBcAMP ( I  mM) prior to cell permeabilization re- 
duced 3H-IP release elicited by carbachol, GTPyS, or 
their combination, whereas basal 3H-IP release was 
unaffected (Fig. 5). Although CT was markedly more 
effective than dBcAMP (28-73% versus 15-44%), the 
ability of both agents to inhibit significantly GTPyS- 
stimulated 3H-IP release suggests that a primary site of 
action of CAMP occurs at or downstream from the G,- 
phospholipase C interaction. Because basal 3H-IP re- 
lease was unaffected by pretreatment with CT or 
dBcAMP, a direct action of cAMP on phospholipase 
C activity appears unlikely. The ability of dBcAMP to 
inhibit PPI turnover in permeabilized cells following 
a 16-h incubation, in contrast to its relative ineffec- 
tiveness in short-term incubations (see Table 2, part 
B), suggests that it may not readily penetrate intact 
SK-N-SH cells. 
In addition to its ability to increase the cAMP con- 
tent of cells, CT is also known to inhibit stimulated 
PPI turnover through its interaction with a G, that 
mediates phospholipase C activation (Lo and Hughes. 
1987; Schnefel et al., 1988). To evaluate this possibility, 
labeled SK-N-SH cells were first permeabilized, pre- 
treated for 30-60 min in the absence or presence of 50 
pg/ml of activated CT, and then incubated with car- 
bachol or GTPyS for another 15 min. Preincubation 
with CT did not inhibit either carbachol- or GTPyS- 
stimulated 3H-IP release, even though ADP-ribosyla- 
tion of membrane proteins was detected under these 
conditions. Thus, either G, in SK-N-SH cells is not a 
substrate for CT, or alternatively, a more extensive in- 
cubation is necessary for ADP-ribosylation of G,. 
Effect of the agonist PGEl on carbachol-stimulated 
3 ~ - 1 ~  release 
The addition of agents that increase cAMP concen- 
trations through mechanisms other than receptor ac- 
tivation results in an inhibition of mAChR-stimulated 
PPI hydrolysis in SK-N-SH cells. To determine whether 
an increase in cAMP concentration elicited by the ad- 
Cholera toxin 
g k  
- z g  m *  2 
- n  0- 
* *  ' I *  
- 
d 
Carbachol GTPyS Carbachol 
GTPyS 
FIG. 5. Pretreatment with either CT or dBcAMP reduces the ability 
of both the agonist carbachol and GTPyS to stimulate 3H-IP release 
from perrneabilized SK-N-SH cells. Cells that had been prelabeled 
with [3H]inosiitol for 3 days were treated with either CT (50 1st 
ml), dBcAMP (1 rnM), or buffer (control) for the last 16 h of labeling. 
Cells were then detached, perrneabilized with digitonin, and in- 
cubated for 15 min at 37°C in the absence or presence of carbachol 
(10 mnn), GTPyS (50 pM), or both. *Significantly different from 
control, p < 0.05. Results shown are means f SEM for triplicate 
samples from a single experiment. Values for basal 3H-IP release 
in the experiment shown were 282 f 25,274 & 15, and 276 t 14 
dpm for control, CT- and dBcAMP-pretreated cells, respectively. 
The concentration of Ca2+ was maintained at 60 nM as previously 
described by Fisher et al. (1989). In three separate experiments 
pretreatment of SK-N-SH cells with CT reduced the carbachol, 
GTPyS, or carbachol plus GTPyS-stimulated release of 3H-IP by 
51 +_ 6, 59 +_ 9, and 47 f 9%, respectively. The corresponding 
values obtained following pretreatment with dBcAMP were 27 
2 9, 23 & 2, and 26 f 7%. respectively. 
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dition of an agonist can produce a similar inhibition, 
the effect of PGEl on carbachol-stimulated 'H-IP re- 
lease was studied. Addition of 30 pM PGEl increased 
cAMP concentrations to 208 +- 34% of control in the 
absence of 1 mM IBMX (n = 3), and to 2,768 k 296% 
of control in the presence of IBMX (n = 9). These 
increases in cAMP concentration were not, however, 
accompanied by a significant inhibition of stimulated 
PPI turnover. Thus, the addition of PGEl alone did 
not inhibit carbachol-stimulated 3H-IP release (-5 
5 9%, n = 5 ) ,  whereas in the presence of IBMX, PGEl 
addition resulted in a 57 k 6% inhibition (n = 5), a 
value similar to that obtained for IBMX alone (51 
It_ 3%, see Table 2, part A). PGE, had no effect on basal 
3H-IP release. Thus, PGEl-mediated increases in cAMP 
do not appear to result in an inhibition of stimulated 
PPI turnover. 
DISCUSSION 
The principal conclusion to emerge from the present 
study is that an increased intracellular concentration 
of cAMP elicited by agents that act at either the level 
of G,, adenylate cyclase, or cAMP phosphodiesterase 
results in an inhibition of stimulated PPI turnover in 
SK-N-SH neuroblastoma. The evidence in favor of this 
conclusion is threefold. First, the addition of CT, an 
agent known to ADP-ribosylate the a-subunit of G, 
and cause its permanent activation (Gilman, 1987), 
resulted in a marked inhibition of carbachol-stimulated 
3H-IP release. Second, inclusion of either FSK, or its 
water-soluble analog, L-85,805 1, both of which directly 
stimulate the catalytic unit of adenylate cyclase (Sea- 
mon and Daly, 1986; Laurenza et al., 1987), also re- 
sulted in an inhibition of stimulated inositol lipid hy- 
drolysis. In contrast, the inactive analog of FSK, 1.9- 
dideoxy FSK (Joost et al., 1988), had little or no effect 
on stimulated PPI turnover. Third, although relatively 
low resting levels of cAMP are present in SK-N-SH 
cells, inhibition of cAMP phosphodiesterase by inclu- 
sion of agents such as IBMX or theophylline resulted 
in increased cAMP concentrations and also inhibition 
of stimulated PPI turnover. 
When SK-N-SH neuroblastomata were extensively 
pretreated with either CT or dBcAMP, the ability of 
either carbachol or GTPyS to stimulate PPI turnover 
in digitonin-permeabilized cells was reduced to a sim- 
ilar extent (Fig. 5). This result indicates that the primary 
inhibitory site of action of cAMP resides either at or 
distal to the G,-phospholipase C interaction, rather 
than at the level of the mAChR or mAChR-G, cou- 
pling. cAMP has also recently been proposed to inhibit 
the activation of phospholipase C by G, in platelets 
(Yada et al., 1989). 
The ability of cAMP to inhibit stimulated PPI turn- 
over has previously been observed for platelets (de 
Chaffoy de Courcelles et al., 1986), neutrophils (Take- 
nawa et al., 1986; Della Bianca et al., 1986), kidney 
(Neylon and Summers, 1988), smooth muscle (Mad- 
ison and Brown, 1988), lymphocytes (Lerner et al., 
1988), and adrenal glomerulosa cells (Guillon et al., 
1988). In contrast, increases in cAMP concentration 
do not appear to inhibit stimulated PPI turnover in 
either hepatocytes (Kaibuchi et al., 1982) or in cerebral 
cortex (Hollingsworth and Daly, 1985). Despite the 
latter observation, our results with SK-N-SH cells (and 
recent observations with NG 108- 15 cells; Campbell 
et al., 1988) suggest that inositol lipid hydrolysis may 
be subject to regulation by the cyclic nucleotide in at 
least some neural tissues. 
Although inhibition of stimulated PPI turnover has 
been observed following receptor-mediated activation 
of adenylate cyclase (Kaibuchi et al., 1982; Della Bianca 
et al., 1986; de Chaffoy de Courcelles et al., 1986), most 
of the evidence implicating a regulatory role for cAMP 
in inositol lipid hydrolysis has been obtained from the 
use of agents that increase cAMP concentrations in- 
dependently of receptor activation. An unexpected 
finding from the present study was that the increases 
in cAMP mediated by PGEl (in contrast to those gen- 
erated through receptor-independent mechanisms) 
were not accompanied by an inhibition of carbachol- 
stimulated 'H-IP release in SK-N-SH cells, even though 
the intracellular concentrations of cAMP were in- 
creased by up to 28-fold in the presence of the agonist. 
Conceivably, two explanations could account for this 
paradoxical result. First, it is possible that the rise in 
cAMP concentration and inhibition of stimulated PPI 
turnover observed in the presence of CT, IBMX, and 
FSK are parallel but unrelated events. For example, in 
addition to its known ability to inhibit cAMP phos- 
phodiesterase, IBMX can block the inhibitory guanine 
nucleotide binding protein, Gi (Parsons et al., 1988), 
and (like FSK) can directly inhibit the glucose trans- 
porter system in adipocytes (Kashiwagi et al., 1983). 
Although the possibility of such a direct inhibitory ac- 
tion of these agents on stimulated PPI turnover in SK- 
N-SH cells cannot be excluded, evidence in favor of 
an intermediary role for cAMP in the inhibition can 
be summarized as follows: (1)  although CT, FSK, and 
IBMX have distinctly different proposed modes of ac- 
tion on the adenylate cyclase system, they affect cAMP 
content and stimulated PPI turnover in a similar man- 
ner; (2) when two of the agents are combined, e.g., CT 
and IBMX or FSK and IBMX, the resulting inhibition 
is less than additive, a result indicative of a common 
site of action for these agents; and ( 3 )  the specificity 
with which the FSK analogs inhibit PPI turnover mir- 
rors their ability to activate adenylate cyclase. An al- 
ternative explanation for the inability of PGE, to inhibit 
PPI turnover may lie in the compartmentation of 
cAMP within SK-N-SH neuroblastoma, such that the 
cellular concentration of CAMP attained in the presence 
of the agonist does not necessarily reflect its concen- 
tration in the biologically relevant compartment. Ev- 
idence to suggest the compartmentalization of both 
cAMP (and CAMP-dependent protein kinase) and ino- 
sitol trisphosphate has been reported for a number of 
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tissues (Spearman and Butcher, 1982; Merritt et al., 
1986; Ambler et al., 1987). A further indication that 
separate metabolic compartments may exist for these 
two second messenger systems within the same cell 
was recently obtained from studies of tracheal smooth 
muscle. In these cells, agents that elevate cAMP result 
in an inhibition of histamine-stimulated PPI turnover, 
but not that mediated by mAChR activation (Madison 
and Brown, 1988). Although an explanation for the 
inability of PGE, to inhibit carbachol-stimulated PPI 
turnover in SK-N-SH cells is not yet apparent, our 
results nonetheless stress the need to evaluate the effects 
of both receptor-mediated and -independent increases 
in cAMP when assessing the regulatory role of this 
cyclic nucleotide on inositol lipid hydrolysis. 
The observation that increases in cAMP can inhibit 
stimulated PPI turnover in some tissues has led to 
speculation over the possible physiological significance 
of such a “cross-talk’’ between the two signaling mech- 
anisms (Nishizuka, 1986; Jakobs et al., 1986). Although 
this remains an attractive hypothesis, two considera- 
tions are pertinent when evaluating this possibility in 
SK-N-SH cells. First, as previously noted, there are 
differential effects of increased cAMP concentrations 
on stimulated PPI turnover dependent on the agent 
employed. Second, in SK-N-SH cells the relationship 
between inositol lipid hydrolysis and adenylate cyclase 
may be additionally complex, because activation of the 
M3 mAChRs on these cells also results in a secondary 
increase in CAMP concentration (Baumgold and Fish- 
man, 1988; Baron and Siegel, 1988). Thus, although 
it is evident that increases in cAMP mediated by the 
addition of certain agents can inhibit stimulated PPI 
turnover in SK-N-SH cells, the physiological signifi- 
cance of this inhibition remains to be determined. 
In summary, the present results indicate that in- 
creases in cAMP concentration mediated by agents that 
act independently of receptor activation inhibit 
mAChR-stimulated PPI hydrolysis in human SK-N- 
SH neuroblastoma cells. These results point to the pos- 
sibility that stimulated inositol lipid hydrolysis may be 
similarly affected by cAMP in other neural prepara- 
tions. 
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